Astellas lowers sales expectations for menopause drug, aims to ‘reproduce’ hype for Veozah with another Super Bowl ad

Astel­las, which is ready­ing a Su­per Bowl ad for its hot flash menopause treat­ment Veozah, sig­nif­i­cant­ly cut the drug’s sales fore­cast for the year, cit­ing slug­gish com­mer­cial up­take.

The Japan­ese drug­mak­er said Mon­day it now ex­pects 7.1 bil­lion yen ($50 mil­lion) in sales of Veozah in fis­cal 2023, down from 53 bil­lion yen ($375 mil­lion). The drug, which was ap­proved by the FDA in May, brought in 3.6 bil­lion yen ($25 mil­lion) through the third quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.